Growth Metrics

Glaukos (GKOS) Short term Debt (2014 - 2021)

Glaukos (GKOS) reported Short term Debt of $279.3 million for Q2 2021, little changed on a QoQ basis from $279.0 million in Q1 2021.

Glaukos (GKOS) has 5 years of Short term Debt data on file, last reported at $279.3 million in Q2 2021.

  • Quarterly Short term Debt changed N/A year-over-year to $279.3 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $279.3 million (changed N/A YoY) and the FY2020 annual result came in at $89.2 million, changed N/A from the prior year.
  • Short term Debt steadied at $279.3 million in Q2 2021 per GKOS's latest filing, from $279.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $279.3 million in Q2 2021 and bottomed at $89.2 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Glaukos 6.00 Bn 5.90 Bn 117.23 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 279.34 Mn
Mar 31, 2021 279.00 Mn
Dec 31, 2020 89.20 Mn
Sep 30, 2016 3.04 Mn
Jun 30, 2016 5.29 Mn
Mar 31, 2016 7.50 Mn
Dec 31, 2015 8.93 Mn
Sep 30, 2015 8.82 Mn
Jun 30, 2015 9.29 Mn
Dec 31, 2014 8.53 Mn